

PTO/SB/08B (12-07)

Approved for use through 12/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Pape	rwork Reduction Ac	of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB co	introi number.	
Substitute for form 1449/PTO			Application Number	10/535 504		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	05/18/2005 Sanders		
			First Named Inventor			
			Art Unit	1645		
(Use as many sheets as necessary)		Examiner Name	Swartz, R			
Sheet 1	of	1	Attorney Docket Number	SAND3.0-003PCT/US		

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the article (when appropriate), title of the page (s), volume issue	 Τ²		
Examiner Initials*	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue item (book, magazine, journal, serial, symposium, symposium, serial, symposium, sympos			
		Rohrbach s, et al, Medline, NLM 11713429, Nov 2001 "Minimally invasive application of Botulinum toxin type A in nasal hypersecretion"			
		Ural Murat et al , Medline NLM 14710908 Dec 2003 "Effect of botulinum Toxin type A on nasal symptoms in patients with allergic Rhititis: etc"			

Examiner	Date	
	Considered	
Signature	 Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.